| Literature DB >> 33421263 |
Christine Maria Schwarz1, Magdalena Hoffmann1,2,3, Christian Smolle1, Michael Eiber1, Bianca Stoiser4, Gudrun Pregartner5, Lars-Peter Kamolz1, Gerald Sendlhofer1,2.
Abstract
RATIONALE ANDEntities:
Keywords: abbreviations; discharge summary; electronic health record; patient safety; risk
Mesh:
Year: 2021 PMID: 33421263 PMCID: PMC9290607 DOI: 10.1111/jep.13533
Source DB: PubMed Journal: J Eval Clin Pract ISSN: 1356-1294 Impact factor: 2.336
Mandatory and optional ELGA headings of the medical DS
| Option | Position | Section | ||
|---|---|---|---|---|
|
| 1 | Letter text | ||
|
| 2 |
| Epicrisis | |
|
| 3 |
| ||
|
| 4 | Rehabilitation goals | ||
|
| 5 | Outcome Measurement | ||
|
| 6 | Measures implemented | ||
|
| 7 |
| ||
|
| 8 |
| ||
|
| 9 |
| ||
|
|
| |||
|
|
| |||
|
|
| |||
|
| 10 | Summary of stay | ||
|
| 11 | Closing remarks | ||
|
| 12 | Allergies, intolerances and risks | Secondary Sections | |
|
| 13 |
Diagnostic findings Possible Subsections: | ||
|
| Pending results | |||
|
| Extracts from collected results | |||
|
| Operation report | |||
|
| Attached collected results | |||
|
| Vital parameters | |||
|
| 14 | Anamnesis | ||
|
| 15 | Previous diseases | ||
|
| Subsection “Previous measures” | |||
|
| 16 | Medication at admission | ||
|
| 17 | Medication administered during the stay | ||
|
| 18 | Living wills and other legal documents | ||
|
| 19 | Supplements | ||
Note: MUST means a mandatory requirement (commandment). Corresponds to the conformity criteria [R] and [M]. SHOULD or RECOMMENDED stands for a recommendation. It is desired and recommended that the requirement should be implemented, but there may be reasons why this is not done. Corresponds to compliance criterion [R2]. CAN or OPTIONAL (MAY, OPTIONAL): The implementation of the requirement is optional, it can also be omitted without compelling reason. Corresponds to the conformity criterion [O].
Reporting of mandatory sections of ELGA in the sampled DS
| Section | 1 = Strongly Agree | 2 = Agree | 3 = Disagree | 4 = Strongly Disagree | Not applicable | Missing data |
|---|---|---|---|---|---|---|
|
| 80 (80%) | 14 (14%) | 6 (6%) | 0 | ||
|
| 98 (98%) | 2 (2%) | 0 | |||
|
| 48 (48%) | 1 (1%) | 51 (51%) | 0 | ||
| Full name of the drug | 35 (35.4%) | 4 (4%) | 3 (3%) | 56 (56.6%) | 1 (1%) | 1 |
| Dose or concentration of the drug | 11 (11%) | 4 (4%) | 2 (2%) | 82 (82%) | 1 (1%) | 0 |
| Dosage form or method of application | 13 (13%) | 7 (7%) | 7 (7%) | 72 (72%) | 1 (1%) | 0 |
| Frequency of administration | 7 (7%) | 2 (2%) | 5 (5%) | 85 (85%) | 1 (1%) | 0 |
|
| 94 (94%) | 6 (6%) | 0 | |||
| Full name of the drug | 88 (88%) | 5 (5%) | 1 (1%) | 6 (6%) | 0 | |
| Dose or concentration of the drug | 75 (75%) | 15 (15%) | 2 (2%) | 8 (8%) | 0 | |
| Dosage form or method of application | 23 (23%) | 17 (17%) | 11 (11%) | 49 (49%) | 0 | |
| Frequency of administration | 44 (44%) | 44 (44%) | 5 (5%) | 7 (7%) | 0 | |
|
| 61 (62.2%) | 14 (14.3%) | 2 (2%) | 21 (21.4%) | 2 | |
| Appointments, control | 66 (66.0%) | 18 (18.0%) | 8 (8.0%) | 8 (8.0%) | 0 | |
| Discharge condition | 24 (24.0%) | 45 (45.0%) | 18 (18.0%) | 13 (13.0%) | 0 | |
| Recommended arrangements for further care | 21 (21.2%) | 28 (28.3%) | 7 (7.1%) | 43 (43.4%) | 1 |
Data presented are numbers of observations, which coincide with percentages due to the total number of 100 DS. MUST means a mandatory requirement (commandment) [M].
Comparison of mandatory ELGA headings between five clinics
| Internal medicine (N = 30) | Dermatology (N = 20) | Surgery (N = 20) | Neurology (N = 8) | Paediatrics (N = 22) | Total (N = 100) |
| |
|---|---|---|---|---|---|---|---|
| Reason for admission |
| ||||||
| 1 Strongly agree | 30 (100.0%) | 19 (95.0%) | 2 (10.0%) | 8 (100.0%) | 21 (95.5%) | 80 (80.0%) | |
| 2 Agree | 0 (0.0%) | 1 (5.0%) | 12 (60.0%) | 0 (0.0%) | 1 (4.5%) | 14 (14.0%) | |
| 3 Disagree | 0 (0.0%) | 0 (0.0%) | 6 (30.0%) | 0 (0.0%) | 0 (0.0%) | 6 (6.0%) | |
| Last medication |
| ||||||
| 1 Strongly agree | 21 (70.0%) | 12 (60.0%) | 0 (0.0%) | 7 (87.5%) | 8 (36.4%) | 48 (48.0%) | |
| 3 Disagree | 1 (3.3%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 1 (1.0%) | |
| 4 Strongly disagree | 8 (26.7%) | 8 (40.0%) | 20 (100.0%) | 1 (12.5%) | 14 (63.6%) | 51 (51.0%) | |
| Appointments, control |
| ||||||
| 1 Strongly agree | 15 (50.0%) | 16 (80.0%) | 20 (100.0%) | 2 (25.0%) | 13 (59.1%) | 66 (66.0%) | |
| 2 Agree | 6 (20.0%) | 2 (10.0%) | 0 (0.0%) | 3 (37.5%) | 7 (31.8%) | 18 (18.0%) | |
| 3 Disagree | 4 (13.3%) | 1 (5.0%) | 0 (0.0%) | 1 (12.5%) | 2 (9.1%) | 8 (8.0%) | |
| 4 Strongly disagree | 5 (16.7%) | 1 (5.0%) | 0 (0.0%) | 2 (25.0%) | 0 (0.0%) | 8 (8.0%) | |
| Discharge condition |
| ||||||
| 1 Strongly agree | 4 (13.3%) | 8 (40.0%) | 2 (10.0%) | 1 (12.5%) | 9 (40.9%) | 24 (24.0%) | |
| 2 Agree | 15 (50.0%) | 5 (25.0%) | 10 (50.0%) | 3 (37.5%) | 12 (54.5%) | 45 (45.0%) | |
| 3 Disagree | 4 (13.3%) | 5 (25.0%) | 6 (30.0%) | 3 (37.5%) | 0 (0.0%) | 18 (18.0%) | |
| 4 Strongly disagree | 7 (23.3%) | 2 (10.0%) | 2 (10.0%) | 1 (12.5%) | 1 (4.5%) | 13 (13.0%) | |
| Recommended arrangements for further care |
| ||||||
| N‐Miss | 0 | 0 | 1 | 0 | 0 | 1 | |
| 1 Strongly agree | 2 (6.7%) | 6 (30.0%) | 9 (47.4%) | 1 (12.5%) | 3 (13.6%) | 21 (21.2%) | |
| 2 Agree | 2 (6.7%) | 8 (40.0%) | 10 (52.6%) | 1 (12.5%) | 7 (31.8%) | 28 (28.3%) | |
| 3 Disagree | 3 (10.0%) | 3 (15.0%) | 0 (0.0%) | 1 (12.5%) | 0 (0.0%) | 7 (7.1%) | |
| 4 Strongly disagree | 23 (76.7%) | 3 (15.0%) | 0 (0.0%) | 5 (62.5%) | 12 (54.5%) | 43 (43.4%) | |
| Full name of the drug (last medication) |
| ||||||
| N‐Miss | 0 | 1 | 1 | 0 | 0 | 2 | |
| 1 Strongly agree | 13 (43.3%) | 12 (63.2%) | 0 (0.0%) | 6 (75.0%) | 4 (18.2%) | 35 (35.7%) | |
| 2 Agree | 3 (10.0%) | 0 (0.0%) | 0 (0.0%) | 1 (12.5%) | 0 (0.0%) | 4 (4.1%) | |
| 3 Disagree | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 3 (13.6%) | 3 (3.1%) | |
| 4 Strongly disagree | 14 (46.7%) | 7 (36.8%) | 19 (100.0%) | 1 (12.5%) | 15 (68.2%) | 56 (57.1%) | |
| Frequency of administration (last medication) |
| ||||||
| N‐Miss | 0 | 1 | 0 | 0 | 0 | 1 | |
| 1 Strongly agree | 1 (3.3%) | 5 (26.3%) | 0 (0.0%) | 1 (12.5%) | 0 (0.0%) | 7 (7.1%) | |
| 2 Agree | 0 (0.0%) | 2 (10.5%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 2 (2.0%) | |
| 3 Disagree | 2 (6.7%) | 2 (10.5%) | 0 (0.0%) | 0 (0.0%) | 1 (4.5%) | 5 (5.1%) | |
| 4 Strongly disagree | 27 (90.0%) | 10 (52.6%) | 20 (100.0%) | 7 (87.5%) | 21 (95.5%) | 85 (85.9%) | |
| Dosage form or method of application (recommended medication) |
| ||||||
| 1 Strongly agree | 3 (10.0%) | 2 (10.0%) | 4 (20.0%) | 3 (37.5%) | 11 (50.0%) | 23 (23.0%) | |
| 2 Agree | 7 (23.3%) | 2 (10.0%) | 1 (5.0%) | 0 (0.0%) | 7 (31.8%) | 17 (17.0%) | |
| 3 Disagree | 2 (6.7%) | 6 (30.0%) | 2 (10.0%) | 1 (12.5%) | 0 (0.0%) | 11 (11.0%) | |
| 4 Strongly disagree | 18 (60.0%) | 10 (50.0%) | 13 (65.0%) | 4 (50.0%) | 4 (18.2%) | 49 (49.0%) | |
| Frequency of administration (recommended medication) |
| ||||||
| 1 Strongly agree | 4 (13.3%) | 10 (50.0%) | 16 (80.0%) | 8 (100.0%) | 6 (27.3%) | 44 (44.0%) | |
| 2 Agree | 24 (80.0%) | 7 (35.0%) | 4 (20.0%) | 0 (0.0%) | 9 (40.9%) | 44 (44.0%) | |
| 3 Disagree | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 5 (22.7%) | 5 (5.0%) | |
| 4 Strongly disagree | 2 (6.7%) | 3 (15.0%) | 0 (0.0%) | 0 (0.0%) | 2 (9.1%) | 7 (7.0%) |
100 most frequently used abbreviations found in the sampled DS
| Nr. | Abbreviation | Frequency | Nr. | Abbreviation | Frequency | Nr. | Abbreviation | Frequency |
|---|---|---|---|---|---|---|---|---|
| 1 | Z.N | 79 | 36 | VHFA | 8 | 71 | MAN | 5 |
| 2 | ST.P | 66 | 37 | AMB | 7 | 72 | NINS | 5 |
| 3 | BDS | 42 | 38 | BCC | 7 | 73 | PD | 5 |
| 4 | E | 34 | 39 | HB | 7 | 74 | PDA | 5 |
| 5 | TGL | 30 | 40 | MR | 7 | 75 | PLAST | 5 |
| 6 | AZ | 29 | 41 | MRT | 7 | 76 | RVOT | 5 |
| 7 | E‐NR | 27 | 42 | OS | 7 | 77 | S.C | 5 |
| 8 | PAT | 22 | 43 | RAPI | 7 | 78 | SHT | 5 |
| 9 | Z.B | 20 | 44 | SIN | 7 | 79 | TF | 5 |
| 10 | GTT | 15 | 45 | SR | 7 | 80 | ASDII | 4 |
| 11 | RE | 14 | 46 | AEZ | 6 | 81 | BA | 4 |
| 12 | STAT | 14 | 47 | AKT | 6 | 82 | CX | 4 |
| 13 | HF | 13 | 48 | CHRON | 6 | 83 | DEXT | 4 |
| 14 | LI | 13 | 49 | CT | 6 | 84 | ENTSPR | 4 |
| 15 | EZ | 12 | 50 | HBA1C | 6 | 85 | HT | 4 |
| 16 | HNO | 12 | 51 | I.E.L | 6 | 86 | I.V | 4 |
| 17 | MAX | 12 | 52 | LA | 6 | 88 | IT | 4 |
| 18 | RR | 12 | 53 | N | 6 | 89 | KC | 4 |
| 19 | V.A | 12 | 54 | O.B | 6 | 90 | KO | 4 |
| 20 | VA | 12 | 55 | TE | 6 | 91 | KU | 4 |
| 21 | IV | 11 | 56 | CCD‐MUXF3 | 5 | 92 | LSF | 4 |
| 22 | V | 11 | 57 | CHIR | 5 | 93 | MEL | 4 |
| 23 | ART | 10 | 58 | CKD | 5 | 94 | NEG | 4 |
| 24 | BZW | 9 | 59 | DD | 5 | 95 | NSTEMI | 4 |
| 25 | COR | 9 | 60 | DG | 5 | 96 | OAD | 4 |
| 26 | HA | 9 | 61 | ED | 5 | 97 | PRÄP | 4 |
| 27 | SPO2 | 9 | 62 | ERG | 5 | 98 | SEK | 4 |
| 28 | UE | 9 | 63 | GESLGE | 5 | 99 | SSW | 4 |
| 29 | US | 9 | 64 | GGF | 5 | 100 | TAPSE | 4 |
| 30 | AV | 8 | 65 | IAS | 5 | |||
| 31 | CRP | 8 | 66 | INKL | 5 | |||
| 32 | DIG | 8 | 67 | IVS | 5 | |||
| 33 | DM | 8 | 68 | KHKIII | 5 | |||
| 34 | DZT | 8 | 69 | LAD | 5 | |||
| 35 | ECP | 8 | 70 | LT | 5 |
The following pre‐processing steps were carried out on the raw data as an attempt to catch and combine different spellings of the same abbreviation: lower/upper case was ignored, blank spaces were removed, points at the end of an abbreviation were ignored, commas were replaced by dots (to catch any commas used as a decimal separator).